Claudin-1 is a mediator and therapeutic target in primary sclerosing cholangitis

IF 33 1区医学 Q1 GASTROENTEROLOGY & HEPATOLOGY

Journal of Hepatology Pub Date : 2025-08-20 DOI:10.1016/j.jhep.2025.08.005

Fabio Del Zompo, Emilie Crouchet, Tessa Ostyn, Zeina Nehme, Mélissa Messé, Frank Juehling, Romain Désert, Angelica T. Vieira, Julien Moehlin, Diana Nakib, Tallulah Andrews, Catia Perciani, Sai Chung, Gary Bader, Ian McGilvray, Chiara Caime, Miki Scaravaglio, Marco Carbone, Pietro Invernizzi, Sheraz Yaqub, Trine Folseraas, Tom H. Karlsen, Gautam Shankar, Mark Primeaux, Punita Dhawan, Jesus M. Banales, Natascha Roehlen, Roberto Iacone, Geoffrey Teixeira, Mathias Heikenwälder, Laurent Mailly, Sonya MacParland, Tania Roskams, Olivier Govaere, Catherine Schuster, Thomas F. Baumert

{"title":"Claudin-1 is a mediator and therapeutic target in primary sclerosing cholangitis","authors":"Fabio Del Zompo, Emilie Crouchet, Tessa Ostyn, Zeina Nehme, Mélissa Messé, Frank Juehling, Romain Désert, Angelica T. Vieira, Julien Moehlin, Diana Nakib, Tallulah Andrews, Catia Perciani, Sai Chung, Gary Bader, Ian McGilvray, Chiara Caime, Miki Scaravaglio, Marco Carbone, Pietro Invernizzi, Sheraz Yaqub, Trine Folseraas, Tom H. Karlsen, Gautam Shankar, Mark Primeaux, Punita Dhawan, Jesus M. Banales, Natascha Roehlen, Roberto Iacone, Geoffrey Teixeira, Mathias Heikenwälder, Laurent Mailly, Sonya MacParland, Tania Roskams, Olivier Govaere, Catherine Schuster, Thomas F. Baumert","doi":"10.1016/j.jhep.2025.08.005","DOIUrl":null,"url":null,"abstract":"Primary sclerosing cholangitis (PSC) is a cholangiopathy associated with high risk of development into end-stage liver disease and hepatobiliary cancer. The pathogenesis is poorly understood, and current clinical care offers limited therapeutic options, primarily relying on liver transplantation. Claudin-1 (CLDN1), a transmembrane protein highly expressed in liver epithelial cells, plays a crucial role in cell-cell communication and signaling. Here we aimed to investigate the functional role of CLDN1 as a mediator and therapeutic target for PSC using patient cohorts combined with murine and patient-derived intervention models.","PeriodicalId":15888,"journal":{"name":"Journal of Hepatology","volume":"12 1","pages":""},"PeriodicalIF":33.0000,"publicationDate":"2025-08-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Hepatology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.jhep.2025.08.005","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Primary sclerosing cholangitis (PSC) is a cholangiopathy associated with high risk of development into end-stage liver disease and hepatobiliary cancer. The pathogenesis is poorly understood, and current clinical care offers limited therapeutic options, primarily relying on liver transplantation. Claudin-1 (CLDN1), a transmembrane protein highly expressed in liver epithelial cells, plays a crucial role in cell-cell communication and signaling. Here we aimed to investigate the functional role of CLDN1 as a mediator and therapeutic target for PSC using patient cohorts combined with murine and patient-derived intervention models.

Abstract Image

查看原文本刊更多论文

Claudin-1是原发性硬化性胆管炎的中介和治疗靶点

原发性硬化性胆管炎（PSC）是一种与发展为终末期肝病和肝癌的高风险相关的胆管疾病。发病机制尚不清楚，目前的临床护理提供的治疗选择有限，主要依赖于肝移植。Claudin-1 （CLDN1）是一种在肝上皮细胞中高度表达的跨膜蛋白，在细胞间通讯和信号传导中起着至关重要的作用。在这里，我们的目的是研究CLDN1作为PSC的介质和治疗靶点的功能作用，使用患者队列结合小鼠和患者来源的干预模型。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Hepatology 医学-胃肠肝病学

CiteScore

46.10

自引率

4.30%

发文量

2325

审稿时长

30 days

期刊介绍： The Journal of Hepatology is the official publication of the European Association for the Study of the Liver (EASL). It is dedicated to presenting clinical and basic research in the field of hepatology through original papers, reviews, case reports, and letters to the Editor. The Journal is published in English and may consider supplements that pass an editorial review.